Journal of the American College of Cardiology Vol. 38, No. 3, by the American College of Cardiology ISSN /01/$20.
|
|
- Gabriel Gardner
- 5 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 38, No. 3, by the American College of Cardiology ISSN /01/$20.00 Published by Elsevier Science Inc. PII S (01) Effect of Glycoprotein IIb/IIIa Receptor Inhibition on Angiographic s During Percutaneous Coronary Intervention in the ESPRIT Trial James C. Blankenship, MD, FACC,* Gudaye Tasissa, PHD, J. Conor O Shea, MD, Elias A. Iliadis, MD,* Fouad A. Bachour, MD, FACC,* David J. Cohen, MD, MSC, Henry K. Lui, MD, FACC, Tift Mann, III, MD, FACC, Eric Cohen, MD, James E. Tcheng, MD, FACC, for the ESPRIT Investigators Danville, Pennsylvania; Durham, North Carolina; Boston, Massachusetts; Jackson, Tennessee; Raleigh, North Carolina; and Toronto, Ontario, Canada OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS We sought to determine whether eptifibatide decreases the incidence of in-laboratory angiographic complications and to determine the relationship of angiographically evident complications to elevations of creatine kinase-mb (CK-MB) enzyme levels during percutaneous coronary intervention. In the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial, eptifibatide during coronary intervention was associated with decreased ischemic complications at 48 h and 30 days. Patients (n 2,064) were randomized to placebo versus eptifibatide (two 180 g/kg boluses 10 min apart and as a continuous infusion of 2 g/kg per min) during percutaneous coronary stenting. Angiographic complications including major dissection, distal embolization, residual thrombus, abrupt closure, residual stenosis 50% and side-branch occlusion were prospectively recorded by the operator. Creatine kinase-mb levels were measured after the procedure and every 6 h thereafter. The incidence of angiographic complications and CK-MB elevation was determined for eptifibatide versus placebo groups. Eptifibatide-treated patients demonstrated nonsignificant trends toward fewer angiographic complications (10 vs. 12% for placebo patients, p 0.13) and, for patients with angiographic complications, fewer subsequent CK-MB elevations (43 vs. 50% for placebo patients, p 0.31). In patients without any angiographic complications, the incidence of CK-MB elevation 3 times the normal was 7% with placebo and 4% with eptifibatide (p 0.003). Eptifibatide during nonurgent coronary stent intervention only minimally (and insignificantly) reduces the incidence of angiographic complications and subsequent CK-MB elevations in patients developing an angiographic complication. The greater effect is to reduce myocardial infarction in patients undergoing otherwise uneventful coronary stent implantation as well as in the overall study population. (J Am Coll Cardiol 2001;38:653 8) 2001 by the American College of Cardiology Procedural complications during coronary intervention are often accompanied by elevation of creatine kinase-mb (CK-MB) enzyme levels. Several studies have associated transient closure, side-branch compromise, dissection, distal embolism and other adverse events during coronary intervention with elevated CK-MB enzymes (1 9). Elevated CK-MB enzymes after coronary intervention are associated with increased long-term risks of cardiac events (1,2,4 9). The Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis (IMPACT) II trial demonstrated that the platelet glycoprotein (GP) IIb/IIIa receptor inhibitor eptifibatide (Integrilin, COR Therapeutics Inc., South From the *Geisinger Medical Center, Danville, Pennsylvania; Duke Clinical Research Institute, Duke University, Durham, North Carolina; Beth Israel Hospital, Boston, Massachusetts; Jackson Madison General, Jackson, Tennessee; Wake Heart Associates, Raleigh, North Carolina; and Sunnybrook Hospital, Toronto, Ontario, Canada. Supported by Cor Therapeutics, South San Francisco, California. Manuscript received January 16, 2001; revised manuscript received April 27, 2001, accepted May 17, San Francisco, California) decreases ischemic complications of coronary intervention (10). These findings were confirmed in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial (11). Neither study (10,11) identified how GP IIb/IIIa inhibitors prevent ischemic complications or whether reduction of angiographic complications during coronary intervention plays a role. We studied angiographic complications during coronary intervention in the ESPRIT trial to determine if they were less frequent in eptifibatide-treated patients. METHODS The ESPRIT trial. The ESPRIT trial was a multicenter, randomized, double-blind, parallel group, placebo-controlled, crossover-permitted clinical trial in North America. The study design and rationale have been previously reported (12). Only those patients scheduled to undergo percutaneous coronary intervention with stent implantation in a
2 654 Blankenship et al. JACC Vol. 38, No. 3, 2001 PTCA s With Eptifibatide September 2001:653 8 Abbreviations and Acronyms CK-MB creatine kinase-mb ESPRIT Enhanced Suppression of the Platelet IIb/ IIIa Receptor with Integrilin Therapy trial GP glycoprotein IMPACT Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis trial MI myocardial infarction Table 1. Incidence of Angiographic s Angiographic Eptifibatide (n 1,039) Placebo (n 1,023) p Value Combined (n 2,062) Major dissection 40 (3.9%) 37 (3.6%) (3.7%) Abrupt closure 10 (1.0%) 11 (1.1%) (1.0%) No reflow 15 (1.4%) 12 (1.2%) (1.3%) Thrombus formation 9 (0.9%) 16 (1.6%) (1.2%) Side-branch closure 35 (3.4%) 50 (4.9%) (4.1%) Distal embolization 10 (1.0%) 5 (0.5%) (0.7%) Residual stenosis 50% 23 (2.2%) 26 (2.5%) (2.4%) TIMI grade flow 3 19 (1.8%) 25 (2.5%) (2.1%) Residual thrombus 5 (0.5%) 10 (1.0%) (0.7%) Any of the above 105 (10.1%) 125 (12.2%) (11.15%) TIMI Thrombolysis In Myocardial Infarction. native coronary artery were eligible. Patients were excluded if the treating physician deemed that pretreatment with a GP IIb/IIIa inhibitor was warranted. Other exclusion criteria included myocardial infarction (MI) within 24 h before randomization, history of bleeding diathesis or chronic warfarin therapy. Patients (n 2,064) were randomized to receive either placebo or eptifibatide in a 1:1 ratio, started immediately before the coronary intervention. Eptifibatide was given as two 180 g/kg boluses 10 min apart and as a continuous infusion of 2 g/kg per min (or 1 g/kg per min in patients with serum creatinine 2 mg/dl) started at the same time as the first bolus and continuing for 18 h to 24 h. Essentially, all patients received concomitant aspirin, and a weightadjusted heparin regimen was recommended (initial bolus of 60 U/kg) with a target activated clotting time between 200 s and 300 s. Heparin infusion after the coronary intervention was strongly discouraged. Treatment with ticlopidine or clopidogrel was stipulated per protocol on the day of the procedure but not permitted before then; the choice of loading dose was left to the treating physician. After the coronary intervention, the investigator recorded any angiographic complications on case report forms. Creatine kinase and CK-MB enzymes were obtained immediately after the procedure and every 6 h for the first 24 h (or until discharge) and were analyzed by a central core laboratory. End points. Angiographic complications are listed in Table 1. The primary end point of the ESPRIT trial was the composite of death, MI, urgent target vessel revascularization and thrombotic bail-out GP IIb/IIIa therapy within 48 h of randomization. The key secondary end point was the composite of death, MI and urgent target vessel revascularization at 30 days. End point MIs included those confirmed as MI after adjudication by a clinical events committee and those identified by elevation of CK/CK-MB isoenzymes to 3 times the upper limit of normal on two occasions measured 6 h apart. Statistical analysis. Data on angiographic complications were available and were analyzed for 2,062 patients. Patients were excluded from subsequent CK and CK-MB analyses if no postintervention CK or CK-MB measurements were available (n 180) or if baseline CK or CK-MB (n 221) was elevated (due to a recent MI). The data evaluated in this study include categorical, ordered categorical and continuous variables. Categorical variables are presented as frequencies with the percentages of patients with the characteristic. Continuous measures are presented as means with SD and medians with 25th and 75th percentiles and ranges. The chi-square test was used to evaluate associations between nonordered categorical variables. For dichotomous variables, the p value from the Fisher exact test is provided where expected cell frequencies were too low for the chi-square test. For the ordered categorical and continuous variables, the Wilcoxon ranksum test was used. A p value of 0.05 was considered statistically significant. RESULTS Baseline clinical characteristics. Patients with angiographic complications and patients without such events were similar with respect to 14 baseline characteristics including atherosclerotic risk factors, prior cardiac events, gender, age, weight and presenting syndrome. Patients with and without angiographic complications also had similar medications before coronary intervention, including similar use of aspirin, thienopyridines and heparin. Baseline lesion characteristics. The incidence of angiographic complications was similar in all three major coronary arteries. Patients with angiographic complications (compared with those without angiographic complications) were more likely to have Thrombolysis In Myocardial Infarction flow grade 0/1 (15 vs. 6%, p 0.001), thrombus (11 vs. 4%, p 0.001) and severe stenosis (mean 90 vs. 86%, p 0.001) at the start of the intervention. Procedural characteristics. Angiographic complications were associated with longer procedure durations; median time was 1.72 (1.32, 2.25) h for patients with events versus 1.3 (0.97, 1.73) h for patients without events (p 0.001). Maximum procedural activated clotting times were similar for patients with (280 [232, 309] s) and without events (264 [233, 304], p 0.47). Eptifibatide and angiographic complications. An angiographic complication occurred in 11% of 2,062 patients who underwent coronary intervention (Table 1). There was a
3 JACC Vol. 38, No. 3, 2001 September 2001:653 8 Blankenship et al. PTCA s With Eptifibatide 655 Table 2. Distribution of CK-MB and CK Enzyme Levels in Patients With Versus Without Angiographic s: Patients With Elevated Baseline CK or CK-MB and Patients With No Available Postprocedure CK or CK-MB Measurements Were Excluded Enzyme Elevation (% of Upper Normal Limits) Angiographic (n 183) CK-MB No Angiographic (n 1,478) Angiographic (n 183) CK No Angiographic (n 1,478) 0% 100% 84 (46%) 1,092 (74%) 136 (74%) 1,369 (93%) 100% 300% 53 (29%) 290 (20%) 32 (18%) 98 (6%) 300% 500% 14 (8%) 49 (3%) 11 (6%) 6 ( 1%) 500% 1,000% 15 (8%) 35 (2%) 4 (2%) 5 ( 1%) 1,000% 17 (9%) 12 ( 1%) 0 (0%) 0 (0%) CK-MB creatine kinase-myocardial band. trend toward fewer events in patients treated with eptifibatide (10.1 vs. 12.2% placebo, p 0.13). There were nonsignificant reductions in thrombus formation (p 0.15), residual thrombus (p 0.18) and side-branch occlusion (p 0.08) in eptifibatide-treated patients. The results were almost identical when analyses were repeated on a 1,661-patient subset that excluded all patients with CK or CK-MB measurements that were either elevated at baseline or not performed after the procedure. Extent of enzyme elevation associated with angiographic complications. The distributions of CK and CK-MB enzymes were studied in patients with normal levels at baseline. Elevated CK-MB levels were found in 56% of patients with angiographic complications and in 26% of patients without such events (Table 2). Creatine kinase-mb levels 3 times the normal were observed in 25% of adverse event patients versus 9% of those without such events (p 0.01). Incidence of CK-MB elevation in patients with angiographic complications. Eptifibatide did not significantly decrease the incidence of any degree of CK-MB elevation above upper normal limits in either the group of patients with or the group without angiographic complications (Table 3). Creatine kinase-mb enzyme levels 3 times the normal upper limits occurred in 21% to 22% of patients with angiographic complications and in 4% to 7% of patients without such events. Only in patients without adverse events was there a difference between eptifibatide and placebo patients (4 vs. 7%, p 0.003). There was a consistent trend toward fewer CK-MB elevations above normal in eptifibatide-treated patients, but this trend was less consistent for CK-MB elevations 3 times the normal limits. Parallel analyses involving CK enzyme levels produced similar results (Table 4). There were no differences in CK elevation between eptifibatide and placebo patients with angiographic complications. In patients without angiographic complications, fewer eptifibatide patients had CK elevation above normal (6 vs. 9% in placebo patients, p 0.033). Angiographic complications and clinical end points. Patients with angiographic complications had a significantly higher incidence of the composite primary clinical end point at 48 h than patients without angiographic complications (26 vs. 5%, p 0.001; Table 5). This association persisted at 30 days. Since death and revascularization procedures were infrequent, most of these differences were due to a higher incidence of MI in patients with angiographic complications. A parallel analysis excluded 180 patients for whom CK or CK-MB data were missing, with nearly identical results observed for the remaining 1,881 patients. Table 3. Incidence of CK-MB Enzyme Elevation Among Patients With Angiographic s (Excluding Patients With Abnormal CK-MB Enzyme Elevation Immediately Before or During Procedure) Angiographic CK-MB >1 Normal CK-MB >3 Normal Eptifibatide Placebo p Value* Eptifibatide Placebo p Value* Major dissection 16/40 (40%) 19/37 (51%) /40 (13%) 8/37 (22%) Distal embolization 4/10 (40%) 3/5 (60%) /10 (30%) 1/5 (20%) Residual thrombus 3/5 (60%) 8/10 (80%) /5 (40%) 4/10 (40%) Abrupt closure 4/10 (40%) 6/11 (55%) /10 (20%) 3/11 (27%) Residual stenosis 50% 6/23 (26%) 11/26 (42%) /23 (4%) 7/26 (27%) Side-branch occlusion 18/35 (51%) 27/50 (54%) /35 (31%) 14/50 (28%) TIMI grade 3 7/19 (37%) 12/25 (48%) /19 (11%) 7/25 (28%) Thrombus formation and no reflow 10/24 (42%) 19/28 (68%) /24 (17%) 12/28 (43%) Any angiographic complication 45/105 (43%) 62/125 (50%) /105 (21%) 27/125 (22%) 0.91 No angiographic complications 197/934 (21%) 201/898 (22%) /934 (4%) 61/898 (7%) *Multiple comparisons and small numbers of individual angiographic complications increase the likelihood that p values 0.05 will occur by chance. Numerator is the number of patients with CK-MB level elevation in this treatment arm who have the complication of interest. Denominator is the number of patients with the complication. CK-MB creatine kinase-myocardial band; TIMI Thrombolysis In Myocardial Infarction.
4 656 Blankenship et al. JACC Vol. 38, No. 3, 2001 PTCA s With Eptifibatide September 2001:653 8 Table 4. Incidence of CK Enzyme Elevation Among Patients With Angiographic s Excluding Patients With Abnormal CK-MB Enzyme Elevation Before or During Procedure Angiographic CK >1 Normal CK >3 Normal Eptifibatide Placebo p Value* Eptifibatide Placebo p Value* Major dissection 5/40 (13%) 9/37 (24%) /40 (5%) 2/37 (5%) Distal embolization 2/10 (20%) 1/5 (20%) /10 (0%) 1/5 (20%) Residual thrombus 2/5 (40%) 4/10 (40%) /5 (40%) 2/10 (20%) Abrupt closure 1/10 (10%) 5/11 (45%) /10 (10%) 2/11 (18%) Residual stenosis 50% 2/23 (9%) 7/26 (27%) /23 (0%) 3/26 (12%) Side-branch occlusion 13/35 (37%) 15/50 (30%) /35 (11%) 6/50 (12%) TIMI grade 3 3/19 (16%) 8/12 (67%) /19 (0%) 4/25 (16) Thrombus formation and no reflow 4/24 (17%) 8/28 (29%) /24 (13%) 3/28 (11%) Any angiographic complication 23/105 (22%) 28/125 (22%) /105 (7%) 10/125 (8%) 0.70 No angiographic complications 56/934 (6%) 77/898 (9%) /934 (0.5%) 8/898 (0.9%) 0.37 *Multiple comparisons and small numbers of individual angiographic complications increase the likelihood that p values 0.05 will occur by chance. Numerator is the number of patients with CK-MB level in this treatment arm who have the complication of interest. Denominator is the number of patients with the complication. CK-MB creatine kinase-myocardial band; TIMI Thrombolysis In Myocardial Infarction. DISCUSSION Table 5. Clinical End Points in Patients With Versus Without Angiographic s During Coronary Intervention Clinical End Point Any (n 230) Angiographic None (n 1,832) p Value 48 h Death 0 (0%) 3 (0.16%) 1.000* Myocardial infarction 55 (23.9%) 93 (5.1%) Revascularization 9 (3.9%) 7 (0.4%) Any of the above 60 (26.1%) 97 (5.3%) days Death 1 (0.4%) 9 (0.5%) Myocardial infarction 55 (23.9%) 108 (5.9%) Revascularization 10 (4.4%) 18 (1.0%) Any of the above 63 (26.1%) 118 (6.4%) *For cells with low expected frequencies, p value of Fisher exact test is reported. The critical findings of this study are several. First, there were nonsignificant trends toward the reduction of several individual angiographic complications in eptifibatidetreated patients and in the overall incidence of angiographic complications among patients undergoing coronary intervention in the ESPRIT trial. However, the 16% relative reduction in angiographic complications observed in the eptifibatide arm did not reach statistical significance. In contrast, eptifibatide decreased the relative incidence of death or MI at 48 h by 43% (p ). Thus, prevention of angiographic complications must contribute only modestly to the clinical benefit imparted by eptifibatide treatment. Eptifibatide s failure to prevent CK-MB elevation in patients with angiographic complications. We expected that eptifibatide would prevent CK-MB elevations among patients with angiographic complications; however, the relative reduction associated with eptifibatide in these patients was only 14% for CK-MB 1 times the normal limit and 5% for CK-MB 3 times the normal limits. Neither reduction approached statistical significance. We conclude that limiting CK-MB elevations in patients with angiographic complications contributes only modestly to the overall clinical effect of eptifibatide. Eptifibatide s effects on CK-MB in patients without angiographic complications. An additional important finding is that the largest eptifibatide effect observed in this study was in patients without angiographic complications. The incidence of large CK-MB elevations ( 3 times the normal) decreased from 7% in placebo patients to 4% in eptifibatide patients (42% relative reduction, p 0.003). Because most of the patients in this study (89%) were free of angiographic complications, this relatively small reduction had the largest impact on the number of patients with ischemic end points. Angiographic complications and ischemic events. Because eptifibatide decreased ischemic complications of intervention in the ESPRIT trial but did not significantly decrease angiographic complications, we questioned whether these two events were associated. Patients with angiographic complications had a fivefold higher risk of a subsequent ischemic event within the first 48 h after coronary intervention (p 0.001). The 11% of patients with angiographic complications accounted for almost 40% of ischemic events by 48 h, suggesting that angiographic complications are associated with subsequent ischemic events. Because both angiographic complications and ischemic events occur after randomization, no statistical inferences can be made regarding causation. Comparison of effects of eptifibatide and placebo on angiographic complications and CK-MB elevations. To compare the effects of eptifibatide, we extrapolated the data reported here to imaginary cohorts of 1,000 patients (Table 6). This analysis is dependent upon the assumption that the effects observed in this report have a high degree of precision. Given this caveat, eptifibatide would decrease the incidence of CK-MB elevation 3 times the normal from 86 patients per 1,000 in placebo patients to 55 patients per 1,000 in eptifibatide-treated patients. This is consistent with the ESPRIT trial finding that death or MI occurred in 8.6% of placebo patients and 4.9% of eptifibatide patients.
5 JACC Vol. 38, No. 3, 2001 September 2001:653 8 Blankenship et al. PTCA s With Eptifibatide 657 Table 6. Effects of Eptifibatide Observed in This Study, Extrapolated to an Imaginary Cohort of 1,000 Patients Placebo (n 1,000) Eptifibatide (n 1,000) Reduction in CK-MB Elevations >3 the Normal Attributable to Eptifibatide Patients with angiographic complications Patients 12.2%* of 1, patients 10.2%* of 1, patients Patients with CK-MB 3 normal 21.6% of patients 21.0% of patients Patients without angiographic complications Patients 87.8%* of 1, patients 89.8%* of 1, patients Patients with CK-MB 3 normal 6.8% of patients 3.8% of patients Total *Table 4; Table 6. CK-MB creatine kinase-myocardial band. Most notably, of 31 CK-MB elevations prevented by eptifibatide, 26 (84%) would occur in patients without angiographic complications. Only five would occur from the prevention of angiographic complications or the prevention of CK-MB elevation in those with angiographic complications. Mechanisms of angiographic complications and CK-MB elevations. Some of the angiographic complications included in this study may be primarily mechanical (e.g., dissection, side-branch occlusion) and not influenced by platelet-receptor inhibition, while other events that do involve angiographically visible thrombus (e.g., thrombus formation, embolization) do not occur sufficiently frequently or are not modulated to a sufficient degree by platelet GP IIb/IIIa inhibition to make the aggregate reduction statistically significant. Interestingly, inspection of our data does not suggest that eptifibatide has any greater benefit in preventing thrombotic complications than in preventing mechanical complications. This study does not provide insight into the specific mechanism by which eptifibatide prevents CK-MB elevation in patients with uncomplicated coronary interventions. It may act after the intervention to prevent platelet deposition on the traumatized lesion and subsequent embolization of platelet thrombi (13). Alternatively, it may prevent the occurrence of minor angiographic complications not included in case report forms in this study. This possibility is supported by other studies, which report angiographic complications in 22% of interventions (7). Implications for practice. There are two implications for clinical practice from this study. First, eptifibatide s failure to prevent angiographic complications during coronary intervention may explain the reluctance of some interventionists to adopt platelet GP IIb/IIIa inhibitors as a uniform standard of clinical practice. This implies that pharmacologic interventions might be more widely accepted if they made procedures obviously easier to perform. Secondly, the results of this study do not support the post hoc use of eptifibatide to prevent ischemic complications of complicated interventions. In the ESPRIT trial, if eptifibatide given prospectively did not prevent angiographic complications or their sequelae, it seems unlikely that eptifibatide started post hoc would be more effective. In contrast, it appears that eptifibatide may be most beneficial when used in a prospective fashion. The paradox remains that the greatest absolute benefit is achieved among patients in whom the procedure appears to have gone smoothly. Study limitations. This study is a retrospective analysis of data obtained prospectively. Reliability of the data concerning angiographic complications may be limited since the complications were self-reported by the investigators and not by a core laboratory blinded to treatment. The lack of statistical significance of eptifibatide effects in the subgroup of patients with angiographic complications must be viewed cautiously since the study was not powered to detect differences in this group. Analyses of the ESPRIT trial and this study were performed on an intention-to-treat basis. Some patients in the placebo arm received bail-out eptifibatide. If bail-out eptifibatide had not been allowed or if analyses had been on a treatment-received basis, a greater eptifibatide effect on angiographic complications might have been observed. Conclusions. Eptifibatide does not significantly decrease the incidence of angiographic complications during nonurgent coronary stent intervention nor the incidence of CK-MB elevation in patients with angiographic complications. Most of the benefit of eptifibatide in preventing CK-MB elevations occurs in patients without angiographic complications. Acknowledgment The authors thank the Duke Clinical Research Institute, Duke University, Durham, North Carolina, for statistical analyses. Reprint requests and correspondence: Dr. James Blankenship, Department of Cardiology, Geisinger Medical Center, 21-60, Danville, Pennsylvania jblankenship@geisinger.edu.
6 658 Blankenship et al. JACC Vol. 38, No. 3, 2001 PTCA s With Eptifibatide September 2001:653 8 REFERENCES 1. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implications of creatine kinase elevation following elective coronary interventions. JAMA 1997;227: Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SE. Significance of mild transient release of creatine kinase-mb fraction after percutaneous coronary interventions. Circulation 1996;94: Kugelmass AD, Cohen DJ, Moscucci M, et al. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol 1994;74: Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol 1991;17: Ohman EM, Tardiff BE. Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization. JAMA 1997;227: Tardiff BE, Califf RM, Tcheng JE, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. J Am Coll Cardiol 1999;33: Kini A, Kini S, Marmur JD, et al. Incidence and mechanism of creatine kinase-mb enzyme elevation after coronary intervention with different devices. Catheter Cardiovasc Interv 1999;48: Mehran R, Dangas G, Mintz GS, et al. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions. Circulation 2000;101: Saucedo JF, Mehran R, Dangas G, et al. Long-term clinical events following creatine kinase myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 2000;35: The IMPACT II Investigators. Randomised placebo-controlled trial of effect of Integrelin on complications of percutaneous coronary intervention. Lancet 1997;349: The ESPRIT Investigators. A randomised, placebo-controlled trial of a novel dosing regimen of eptifibatide in planned coronary stent implantation. Lancet 2000;356: O Shea JC, Madan M, Cantor WJ, et al. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention. Am Heart J 2000;140: Topol EJ, Yadav JS. Recognition of importance of embolization in atherosclerotic vascular disease. Circulation 2000;101:
Clinical Outcomes After Detection of Elevated Cardiac Enzymes in Patients Undergoing Percutaneous Intervention
88 JACC Vol. 33, No. 1 Clinical Outcomes After Detection of Elevated Cardiac Enzymes in Patients Undergoing Percutaneous Intervention BARBARA E. TARDIFF, MD, ROBERT M. CALIFF, MD, FACC, JAMES E. TCHENG,
More informationMortality Risk Conferred by Small Elevations of Creatine Kinase-MB Isoenzyme After Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 42, No. 8, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)01044-1
More informationTHE ECONOMICS OF ADJUNCTIVE THERAPIES IN CORONARY ANGIOPLASTY: DRUGS, DEVICES, OR BOTH?
THE ECONOMICS OF ADJUNCTIVE THERAPIES IN CORONARY ANGIOPLASTY: DRUGS, DEVICES, OR BOTH? Paul I. Oh, 1 Eric A. Cohen, 2 Nicole Mittmann, 3, 4 Soo Jin Seung 4 1 Division of Clinical Pharmacology, Sunnybrook
More informationJournal of the American College of Cardiology Vol. 44, No. 9, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 44, No. 9, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.05.085
More informationAre We Making Progress With Percutaneous Saphenous Vein Graft Treatment? A Comparison of 1990 to 1994 and 1995 to 1998 Results
Journal of the American College of Cardiology Vol. 38, No. 1, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01324-9 Are We
More informationInterventional Cardiology
Clinical Investigations Interventional Cardiology Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Insights from the very early outcomes in the
More informationCreatine kinase-mb elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes
European Heart Journal (2004) 25, 313 321 Clinical research Creatine kinase-mb elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes M.T.
More informationMyocardial Damage in Successful Single Vessel Coronary Angioplasty as Assessed by Creatinine Kinase and its Myocardium Band Isoenzyme Levels
ORIGINAL ARTICLE Myocardial Damage in Successful Single Vessel Coronary Angioplasty as Assessed by Creatinine Kinase and its Myocardium Band Isoenzyme Levels Shahid Abbas, Farhan Tayyab, Naseer Ahmed Samor,
More informationHeart Online First, published on December 30, 2005 as /hrt
Heart Online First, published on December 30, 2005 as 10.1136/hrt.2005.078758 Attributable risk of clinical endpoints Clinical endpoint definitions following percutaneous coronary intervention and their
More informationTreatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement
Treatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement Pharmaceutical Care Project Outcomes Literature Evaluation
More informationClinical Investigations
Clinical Investigations Risk Factors of Cardiac Troponin T Elevation in Patients with Stable Coronary Artery Disease After Elective Coronary Drug-Eluting Stent Implantation Zhang-Wei Chen, MD; Ju-Ying
More informationClopidogrel Date: 15 July 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationImpact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting
Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting The TARGET Trial* Gregg W. Stone, MD; David J. Moliterno,
More informationPercutaneous coronary intervention (PCI), in
ECONOMIC IMPLICATIONS OF THE USE OF DIRECT THROMBIN INHIBITORS IN PERCUTANEOUS CORONARY INTERVENTION David J. Cohen, MD, MSc * ABSTRACT More than 1.2 million percutaneous coronary intervention (PCI) procedures
More informationbivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company
bivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company 06 August 2010 The Scottish Medicines Consortium (SMC) has completed its
More informationTreatment of Saphenous Vein Bypass Grafts With Ultrasound Thrombolysis. A Randomized Study (ATLAS)
Treatment of Saphenous Vein Bypass Grafts With Ultrasound Thrombolysis A Randomized Study (ATLAS) Mandeep Singh, MD; Uri Rosenschein, MD; Kalon K.L. Ho, MD; Peter B. Berger, MD; Richard Kuntz, MD; David
More informationCorrelates of Adverse Events During Saphenous Vein Graft Intervention With Distal Embolic Protection
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 2, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.01.002 Correlates
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationThe use of percutaneous coronary intervention (PCI) as
Antithrombotic Therapy During Percutaneous Coronary Intervention The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Jeffrey J. Popma, MD; Peter Berger, MD; E. Magnus Ohman, MD, FCCP;
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationIschemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy
Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Physician, Professor of Medicine Department of Cardiology,
More informationP ostprocedural creatine kinase and its MB isoform
1181 INTERVENTIONAL CARDIOLOGY AND SURGERY Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease T Nageh, R A Sherwood, B M Harris, M R Thomas... See
More informationThe risk of death or ischemic events in patients with
Prediction of Outcome after Percutaneous Coronary Intervention for the Acute Coronary Syndrome Annapoorna S. Kini, MD, Paul C. Lee, MD, Cristina A. Mitre, MD, Michael C. Kim, MD, Mazullah Kamran, MD, Mary
More informationA Pooled Analysis of Five Randomized Clinical Trials
Lack of Benefit From Intravenous latelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for ercutaneous Interventions of Aortocoronary Bypass Grafts A ooled Analysis of Five Randomized
More informationJournal of the American College of Cardiology Vol. 45, No. 9, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 45, No. 9, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.030
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationFacilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
More informationAnti-thrombotic management in interventional cardiology
Chapter 8 Anti-thrombotic management in interventional cardiology James Tcheng, Steve Kindsvater Introduction Since the dawn of the interventional age, the need for anti-thrombotic therapy during percutaneous
More informationCritical Review Form Therapy Objectives: Methods:
Critical Review Form Therapy Clinical Trial Comparing Primary Coronary Angioplasty with Tissue-Plasminogen Activator for Acute Myocardial Infarction (GUSTO-IIb), NEJM 1997; 336: 1621-1628 Objectives: To
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationKorea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea
Left Main Disease versus Non Left Main Disease in Acute Myocardial Infarction Patients in Real world Clinical Practice : Lessons from Korea Acute Myocardial Infarction Registry (KAMIR) Seung-Woon Rha*,
More informationContemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease
Contemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease A Comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationCardiac Troponin I Levels and Clinical Outcomes in Patients With Acute Coronary Syndromes The Potential Role of Early Percutaneous Revascularization
Journal of the American College of Cardiology Vol. 34, No. 6, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00434-9 Cardiac
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationJournal of the American College of Cardiology Vol. 36, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00923-2 Facilitation
More informationJAMA. 2004;292:
ORIGINAL CONTRIBUTION Long-term Efficacy of and Provisional Blockade vs Heparin and Planned Blockade During Percutaneous Coronary Revascularization REPLACE-2 Randomized Trial A. Michael Lincoff, MD Neal
More informationScottish Medicines Consortium
Scottish Medicines Consortium bivalirudin 250mg for injection or infusion (Angiox ) (156/05) Nycomed UK Ltd No. 4 February, 2005 The Scottish Medicines Consortium has completed its assessment of the above
More informationLink between effectiveness and cost data Costing was conducted prospectively on the same patient sample as that used in the effectiveness analysis.
Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention Rabah M, Mason D, Muller D W, Hundley R, Kugelmass
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationMethods The PARAGON-B trial
Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial Kenneth W. Mahaffey, MD, a Matthew T. Roe, MD, a Christopher K. Dyke,
More informationBolus-Only Platelet Glycoprotein IIb/IIIa Inhibition During Percutaneous Coronary Intervention
Original Contribution Bolus-Only Platelet Glycoprotein IIb/IIIa Inhibition During Percutaneous Coronary Intervention Jonathan D. Marmur, MD, Shyam Poludasu, MD, Ajay Agarwal, MD, Pompeiu Vladutiu, MD,
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationThe Effects of Aspirin and Clopidogrel Response on Myonecrosis After Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 6, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.08.017 The Effects
More informationDefining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention
Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention Aggregate Results From 6 Randomized, Controlled Trials Derek P. Chew, MBBS; Deepak L. Bhatt, MD; A. Michael Lincoff,
More informationC.R.E.D.O. Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial
Clopidogrel for the Reduction of Events During Observation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial From Steinhubl et al, JAMA 2002;228:2411-20
More informationTarget vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI
Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI Gamal Abdelhady, Emad Mahmoud Department of interventional
More informationAntiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Franz-Josef Neumann Herz-Zentrum Bad Krozingen Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
More informationRole of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women
Interventional Cardiology Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women Warren J. Cantor, MD, a Julie M. Miller, MD, b Anne S. Hellkamp,
More informationEffect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden
More informationEarly Exercise After Coronary Stenting Is Safe
Journal of the American College of Cardiology Vol. 42, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)01122-7
More informationAtherectomy: Jetstream and Directional. George S. Chrysant, M.D.
Atherectomy: Jetstream and Directional George S. Chrysant, M.D. Disclosures Abbott Vascular: MAB, consultant, proctor Abiomed: consultant Boston Scientific: MAB, consultant, proctor Medicines Company:
More informationInfluence of Planned Six-Month Follow-Up Angiography on Late Outcome After Percutaneous Coronary Intervention A Randomized Study
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01476-0 Influence
More informationJournal of the American College of Cardiology Vol. 48, No. 11, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 11, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.12.084
More informationRecurrent Thrombosis in a Case of Coronary Ectasia with Large Thrombus Burden Successfully Treated by Adjunctive Warfarin Therapy
Case Report Acta Cardiol Sin 2013;29:462 466 Recurrent Thrombosis in a Case of Coronary Ectasia with Large Thrombus Burden Successfully Treated by Adjunctive Warfarin Therapy Hung-Hao Lee, 1 Tsung-Hsien
More informationAssociation Between CK-MB Elevation After Percutaneous or Surgical Revascularization and Three-Year Mortality
Journal of the American College of Cardiology Vol. 40, No. 11, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02538-X
More informationPercutaneous Coronary Interventions Without On-site Cardiac Surgery
Percutaneous Coronary Interventions Without On-site Cardiac Surgery Hassan Al Zammar, MD,FESC Consultant & Interventional Cardiologist Head of Cardiology Department European Gaza Hospital Palestine European
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationRandomized Evaluation of the TriActiv Balloon-Protection Flush and Extraction System for the Treatment of Saphenous Vein Graft Disease
Journal of the American College of Cardiology Vol. 46, No. 9, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.073
More informationInternational Journal of Collaborative Research on Internal Medicine & Public Health (IJCRIMPH)
Same-day discharge after percutaneous coronary intervention in light of the society for cardiovascular angiography and intervention's proposed guidelines: A single-center experience Yazan Khouri, Sachin
More informationPoint-of-Care Assessment of Platelet Reactivity After Clopidogrel to Predict Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 3, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/10/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2009.12.012 Point-of-Care
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationAcute coronary syndrome (ACS) is an
OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationHealth technology Abciximab use in high-risk patients undergoing percutaneous transluminal coronary angioplasty.
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in highrisk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study van Hout B A, Bowman L,
More informationNURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS EPTIFIBATIDE (INTEGRILIN) PROTOCOL
NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE S EPTIFIBATIDE (INTEGRILIN) I. PURPOSE: A. Integrilin (Eptifibatide) is a specific and potent inhibitor of the platelet receptor glycoprotein
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationHealth technology The use of coronary stenting versus primary balloon angioplasty (PTCA) in acute myocardial infarction (AMI).
Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (Stent-PAMI) trial Cohen D J, Taira D A, Berezin R, Cox D A,
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationThrombus Aspiration before PCI: Routine Mandatory. Professor Clinical Cardiology Academic Medical Center University of Amsterdam
Seoul, 27 April TCT AP 2010 Thrombus Aspiration before PCI: Routine Mandatory Robbert J de Winter MD PhD FESC Professor Clinical Cardiology Academic Medical Center University of Amsterdam AMC Amsterdam
More informationIntra-Procedural Stent Thrombosis
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 6, NO. 1, 2013 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.08.018
More informationMETHODS OBJECTIVES BACKGROUND METHODS
Journal of the American College of Cardiology Vol. 36, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00814-7 Platelet
More informationIs it safe to discharge patients 24 hours after uncomplicated successful primary percutaneous coronary intervention
Is it safe to discharge patients 24 hours after uncomplicated successful primary percutaneous coronary intervention DA Jones, J Howard, S Gallagher, KS Rathod, A Jain, S Mohiddin, C Knight, A Mathur, EJ
More informationResults of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies
Intracoronary Radiation Therapy Improves the Clinical and Angiographic Outcomes of Diffuse In-Stent Restenotic Lesions Results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationProspective Comparison of Hemorrhagic Complications After Treatment With Enoxaparin
Prospective Comparison of Hemorrhagic Complications After Treatment With Versus Unfractionated Heparin for Unstable Angina Pectoris or Non ST-Segment Elevation Acute Myocardial Infarction Scott D. Berkowitz,
More informationNovel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)
Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Shaul Atar, MD Department of Cardiology Faculty of Medicine of the Galilee Western Galilee Medical Center, Nahariya, Israel TIMI Risk Score Age 65
More informationThe beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome
International Journal of Cardiology 137 (2009) 246 251 www.elsevier.com/locate/ijcard The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More informationJournal of the American College of Cardiology Vol. 52, No. 22, by the American College of Cardiology Foundation ISSN /08/$34.
Journal of the American College of Cardiology Vol. 52, No. 22, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.021
More informationStatistical analysis plan
Statistical analysis plan Prepared and approved for the BIOMArCS 2 glucose trial by Prof. Dr. Eric Boersma Dr. Victor Umans Dr. Jan Hein Cornel Maarten de Mulder Statistical analysis plan - BIOMArCS 2
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationThe New England Journal of Medicine INTRAVASCULAR GAMMA RADIATION FOR IN-STENT RESTENOSIS IN SAPHENOUS-VEIN BYPASS GRAFTS
INTRAVASCULAR GAMMA RADIATION FOR IN-STENT RESTENOSIS IN SAPHENOUS-VEIN BYPASS GRAFTS RON WAKSMAN, M.D., ANDREW E. AJANI, M.D., R. LARRY WHITE, M.D., ROSANNA C. CHAN, M.D., LOWELL F. SATLER, M.D., KENNETH
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More information